Efficacy of using zinc oxide nanoparticle as a substitute to antibiotic growth promoter and zinc sulphate for growth performance, antioxidant capacity, immunity and intestinal barrier function in broilers

Author: Yu, Caiyun ; Wang, Tian ; Li, Zhihua ; Wang, Chao ; Zhang, Jiaqi ; Liu, Huijuan ; Zhou, Binbin ; Zhang, Xuhui

Dietary zinc oxide nanoparticle (ZnO NP) possessing multiple biol. activities might be a potential substitute for the combination of ZnSO4 and antibiotic growth promoter in broiler diets.Therefore, this study was conducted to investigate the efficacy of dietary ZnO NP as a substitute to the combination of ZnSO4 and xanthomycin for growth, antioxidant capacity, immunity, intestinal barrier and liver function in broilers.Arbor Acres chicks (n = 320) were assigned to 5 treatments with 8 replicates.Birds received a basal diet supplemented with 80 mg/kg ZnSO4 plus 5 mg/kg xanthomycin (ZnSO4 + Xanthomycin) or 0 (neg. control, NC), 40, 80, and 160 mg/kg ZnO NP for 42 days.The average daily gain, average daily feed intake and feed-to-gain ratio showed dose-dependent increases with the increasing level of dietary ZnO NP during the 21-42 day and 1-42 day stages.The final body weight (42 d) and serum concentrations of insulin-like growth factor 1 and growth hormone increased linearly with the increasing level of dietary ZnO NP.In addition, 80 mg/kg ZnO NP increased the serum concentrations of IgA, IgG, IgM, andinterleukin-10 and peroxidase activity, the jejunal mucosal villus height, villus width and goblet cell numbersDietary 80 or 160 mg/kg ZnO NP significantly altered mRNA abundances of genes related to antioxidant status, intestinal barrier and immunity in the jejunal mucosa.These results indicated that dietary supplementation with 40-160 mg/kg ZnO NP caused no obvious neg. effects on liver function, but effectively improved growth performance, intestinal barrier function, immunity and antioxidant capacity.HighlightsDietary 40-160 mg/kg zinc oxide nanoparticle (ZnO NP) improved growth performance and enhanced immunity of broilers without obvious neg. effects on liver function.Dietary 40-160 mg/kg ZnO NP improved intestinal barrier and intestinal morphol., and enhanced antioxidant capacity via Nrf2/HO-1 pathway.Doses of 40-80 mg/kg ZnO NP were suggested to alternate the combination of 80 mg/kg ZnSO4 and 5 mg/kg xanthomycin in diets of broilers.

01 Dec 2016·Journal of Animal Physiology and Animal NutritionQ3 · AGRICULTURAL & FORESTRY SCIENCE

Effects of dietary supplementation of synbiotics on growth performance, intestinal morphology, sIgA content and antioxidant capacities of broilers

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Yang, H. L. ; Min, Y. N. ; Gao, Y. P. ; Xu, Y. X.

SummaryToday, several strategies are being used to decrease the serious effects of antibiotics abuse on broilers industry and public health, among which synbiotics are one of the most promising antibiotic alternative. This study was undertaken to assess the effects of synbiotics, which composed of probiotics (Bacillus subtilis) and prebiotics (xylooligosaccharide and mannanoligosaccharide), on growth performance, intestinal morphology, sIgA content and antioxidant parameters of broilers. Four hundred and fifty one‐day‐old commercial Cobb48 broilers were assigned to five treatments consisting of six replicates of 15 birds each pen. Five dietary treatments include basal diets (control), basal diets plus antibiotics (4 mg/kg Xanthomycin), basal diets plus 1 g of probiotics B. subtilis product/kg of diets (4 × 108 cfu/kg), basal diets plus 150 mg/kg xylooligosaccharide (35%) and 1 g/kg mannanoligosaccharide (75%), and basal diets plus synbiotics (1 g of probiotics B. subtilis product/kg of diets (4 × 108 cfu/kg), 150 mg/kg xylooligosaccharide (35%) and 1 g/kg mannanoligosaccharide (75%). The results demonstrated that on 21 and 42 days, dietary supplementation of the synbiotics significantly increased daily weight gain (p < 0.05), feed efficiency (p < 0.05), the villus height and villus:crypt ratio in the duodenum, jejunum and ileum (p < 0.05), as well as intestinal mucosa sIgA content (p < 0.05), serum T‐SOD activity (p < 0.05) and lysozyme content (p < 0.05), comparing with control group. In conclusion, synbiotics (B. subtilis and xylooligosaccharide and mannanoligosaccharide) is one of the safe and ideal dietary supplementations to increase broilers' growth performance by improving small intestinal morphology, sIgA content and antioxidant capabilities.

01 Feb 2006·Journal of Molecular Modeling

Non-stochastic and stochastic linear indices of the molecular pseudograph’s atom-adjacency matrix: a novel approach for computational in silico screening and “rational” selection of new lead antibacterial agents

Article

Author: Martinez, Yamile ; Zaldivar, Vicente Romero ; Bernal, Milagros Garcia ; Marrero-Ponce, Yovani ; Castro, Eduardo A. ; Abalo, Ricardo Grau ; Marrero, Ricardo Medina ; Torrens, Francisco

A novel approach (TOMOCOMD-CARDD) to computer-aided "rational" drug design is illustrated. This approach is based on the calculation of the non-stochastic and stochastic linear indices of the molecular pseudograph's atom-adjacency matrix representing molecular structures. These TOMOCOMD-CARDD descriptors are introduced for the computational (virtual) screening and "rational" selection of new lead antibacterial agents using linear discrimination analysis. The two structure-based antibacterial-activity classification models, including non-stochastic and stochastic indices, classify correctly 91.61% and 90.75%, respectively, of 1525 chemicals in training sets. These models show high Matthews correlation coefficients (MCC=0.84 and 0.82). An external validation process was carried out to assess the robustness and predictive power of the model obtained. These QSAR models permit the correct classification of 91.49% and 89.31% of 505 compounds in an external test set, yielding MCCs of 0.84 and 0.79, respectively. The TOMOCOMD-CARDD approach compares satisfactorily with respect to nine of the most useful models for antimicrobial selection reported to date. Finally, an in silico screening of 87 new chemicals reported in the anti-infective field with antibacterial activities is developed showing the ability of the TOMOCOMD-CARDD models to identify new lead antibacterial compounds.

100 Deals associated with Guamecycline Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Guamecycline Hydrochloride	-	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	China	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis